Private equity firm KSL Capital Partners has completed the final closing of KSL Capital Partners III, which will specialise in investments in travel and leisure businesses. With in excess of USD2 billion in commitments, the final closing significantly exceeded the original target amount of USD1.5 billion.   Investors in the fund include public and private pensions, foundations, endowments, institutions and high net worth individuals and families. KSL was founded by Michael Shannon and Eric Resnick in 2005. KSL currently has in excess of USD3.5 billion in equity commitments under management. “This new Fund will utilise the same investment principles we

Foley & Lardner LLP has launched Foley Ventures, a USD4 million venture capital fund exclusively to invest in or with Foley clients. The development of Foley Ventures is a direct result of the firm’s extensive experience and insight gained through working with numerous private equity and venture capital funds and emerging companies. Recognising that clients need more than legal insights to succeed, the firm launched Foley Ventures to have the ability to invest in or alongside clients. “We felt that establishing a venture fund was the next logical step in support of our clients dealing with sophisticated financing issues,” says

Warburg Pincus, Trilantic Capital Partners, ZAM Ventures have all agreed to make an investment in newly-formed oil and gas exploration and production company Velvet Energy Ltd. Members of Velvet Energy’s management team and select board members, are also investing in the company.   Velvet Energy, which focuses on the Western Canadian Sedimentary Basin (WCSB) is led by Ken Woolner, a geological engineer by training, and an entrepreneur with a successful track record in the oil and gas industry spanning over 20 years. The company plans to utilise advanced drilling and completion technologies to enhance production and returns in established areas

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage hospital pharmaceuticals, has successfully raised EUR8.2m (CHF10m/USD12m) from Inventages Venture Capital (Inventages) in its first institutional (Series A) financing round. "We are delighted to have successfully completed this fundraising which serves as further validation of the potential of ST10-021 as a novel treatment for iron deficiency anaemia and Shield’s development strategy," says Carl Sterritt, Chief Executive Officer and Co-Founder of Shield Therapeutics. "We look forward to working closely with the Inventages team to benefit from both their experience of working with high-growth companies like

Texas-based private equity firm Teakwood Capital has acquied Clockwork Solutions Inc (CSI), a provider of total-life-cycle Performance Prediction and Risk Management solutions for asset-intensive major industrial companies, military organisations and government agencies.    CSI delivers solutions that maximise equipment, system, and fleet availability while minimising life-cycle operations and maintenance costs. Equipment down time is reduced, inventory is minimised and better positioned, system-wide asset availability is increased and new opportunities to improve profitability are identified. CSI’s solutions serve major industrial operators in the Aerospace & Defence, Power Generation, Refining and Process markets. The majority of CSI’s clients are Fortune 500 companies and